IDH Wild GBM patients trial Nomotto prediction survival

With the in-depth study of the molecular biology characteristics of glioblastoma (GBM), the prediction of patient's survival is no longer a general "14 to 16 months", but should be based on the actual situation of each patient, individualized predictionHaley Gittleman, of the Department of Population and Quantitative Health Sciences at Case Western Reserve University School of Medicine in Ohio, and others studied clinical data on idh wild GBM patients admitted to neurosurgery at the Ohio Brain Tumor Center (OBTS) and the University of California, San Francisco (UCSF) and presented a prognosis prediction model, nomogram, for clinical useThe results were published online in May 2019 by Neuro-Oncology Advancesstudy methods
179 cases of OBTS from 2007 to 2017 and 122 newly diagnosed BGM patients with UCSF, clinical data including diagnostic age, sex, range of tumor removal, simultaneous chemotherapy, KPS score, MGMT methylation and IDH mutation (Table 1)Table 1Clinical data on newly diagnosed patients with primary IDH wild glioblastoma (OBTS and UCSF, 2007-2017)the results of the studysurvival analysis using Cox scale risk regression, random survival forest method and recursive zoning analysis, and adjusted for some known prognostic factorsThe results are shown in Tables 2, 3, Figure 1, Figure 2 and Figure 3Table 2Newly Diagnosed Multivariate Cox Proportional Risk Regression Model (OBTS and UCSF, 2007-2017) in patients with idh wild glioblastomaTable 3Cox proportional risk (CPH), survival forest (RSF) consistency index and corresponding 95% confidence interval (RPA) as well as recursive distribution analysis in newly diagnosed IDH wild glioblastoma patients at 12, 18 and 24 monthsFigure 1Kaplan-Meler survival curve, (A) unadjusted, and (B) adjustments to diagnostic age and KPS scores in patients with newly diagnosed IDH wild glioblastomaMap 2 Nomode map is used to predict the survival of 12, 18 and 24 months in newly diagnosed idh wild glioblastoma patients (OBTS, 2007-2017) Figure 3 Forecast 12-month (A), 18-month (B) and 24-month (C) survival test data, as well as calibration curves for 12 months (D), 18 months (E) and 24-month lifetime spree in newly diagnosed IDH wild glioblastoma patients conclusions authors believe that nomodes are effective in predicting the survival of newly diagnosed IDH mutant glioblastoma Factors that prolong survival may include young patients, women, tumor totals, simultaneous chemotherapy, high KPS scores, and MGMT methylation When a physician is consulted by a patient's family, Nomotto will help to give the ideal treatment plan.